IARC WORKING GROUP ON THE EVALUATION OF CARCINOGENIC RISKS TO HUMANS: SOME ANTIVIRAL AND ANTINEOPLASTIC DRUGS, AND OTHER PHARMACEUTICAL AGENTS

Lyon, 12–19 October 1999

LIST OF PARTICIPANTS

Members
D.E. Barker, The CORE Center for Infectious Diseases, Cook County Hospital, Division of Infectious Diseases, 2020 W. Harrison Street, Chicago, IL 60612, United States
T.A. Dragani, Istituto Nazionale dei Tumori, via G. Venezian 1, 20133 Milan, Italy
J.K. Dunnick, National Institute of Environmental Health Sciences, PO Box 12233, Research Triangle Park, NC 27709, United States
C.A. Felix, Division of Oncology, The Children’s Hospital of Philadelphia, Abramson Pediatric Research Center, Room 902B, 3516 Civic Center Boulevard, Philadelphia, PA 19104-4318, United States
L.R. Ferguson, Auckland Cancer Society Research Centre, Faculty of Medical and Health Science, The University of Auckland, Private Bag 92019, Auckland 1000, New Zealand
S.P. Joel, Medical Oncology, St Bartholomew’s Hospital, West Smithfield, London EC1A 7BE, United Kingdom
R. von Kries, Institute for Social Pediatrics and Adolescent Medicine, Ludwig-Maximilians University, Heiglofsstrasse 63, 81377 Munich, Germany
F.E. van Leeuwen, Department of Epidemiology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
J. Little, Institute of Medical Sciences, Department of Medicine & Therapeutics, University of Aberdeen Medical School, Polwarth Building, Foresterhill, Aberdeen AB9 2ZD, United Kingdom
S. Olin, International Life Sciences Institute, Risk Science Institute, 1126 Sixteenth Street NW, Washington, DC 20036, United States
J.H. Olsen, Danish Cancer Society, Institute of Cancer Epidemiology, Box 839, 2100 Copenhagen Ø, Denmark
M.C. Poirier, Carcinogen–DNA Interactions Section, National Cancer Institute, Building 37, Room 2A05, 37 Convent Drive, Bethesda, MD 20892-4255, United States (Chairperson)

M.J. Shearer, The Vitamin K Research Unit of the Haemophilia Centre, The Rayne Institute, 4th Floor Lambeth Wing, St Thomas’s Hospital, London SE1 7EH, United Kingdom

W. Slikker, Jr, Division of Neurotoxicology, National Center for Toxicological Research, Food and Drug Administration, Jefferson, AR 72079-9502, United States

F.M. Sullivan, Harrington House, 8 Harrington Road, Brighton, East Sussex BN1 6RE, United Kingdom

V. Turusov, Blokhin Cancer Research Centre, Russian Academy of Medical Sciences, Kashirskoye Shosse 24, 115478 Moscow, Russian Federation

V.E. Walker, Wadsworth Center for Laboratories and Research, New York State Department of Health, Empire State Plaza, PO Box 509, Albany, NY 12201-0509, United States

Representative/Observer

Representative of the National Cancer Institute

S.M. Sieber, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Executive Plaza North, 6100 Executive Boulevard, Rockville, MD 20852, United States

Secretariat

E. Heseltine (Editor), Lajarthe, 24290 St Léon-sur-Vézère, France

IARC

R. Baan, Unit of Carcinogen Identification and Evaluation

P. Brennan, Unit of Environmental Cancer Epidemiology

M. Friesen, Unit of Gene–Environment Interactions

Y. Grosse, Unit of Carcinogen Identification and Evaluation

V. Krutovskikh, Unit of Multistage Carcinogenesis

C. Malaveille, Unit of Endogenous Cancer Risk Factors

D. McGregor, Unit of Carcinogen Identification and Evaluation

C. Partensky, Unit of Carcinogen Identification and Evaluation

J. Rice, Unit of Carcinogen Identification and Evaluation (Head of Programme)

J. Wilbourn, Unit of Carcinogen Identification and Evaluation (Responsible Officer)

Technical assistance

M. Lézère

A. Meneghel

D. Mietton

J. Mitchell
PARTICIPANTS

E. Perez
S. Reynaud
J. Thévenoux